Antiviral remdesivir prevents disease progression in monkeys with COVID-19

Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19, according to National Institutes of Health scientists.

This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19. Photo: NIAID-RML

The study was designed to follow dosing and treatment procedures used for hospitalized COVID-19 patients being administered remdesivir in a large, multi-center, clinical trial led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

The findings are not yet peer-reviewed and should not be considered clinical advice, but are being shared to assist the public health response to COVID-19.

The current study of remdesivir, a drug developed by Gilead Sciences Inc. and NIAID-supported investigators, involved two groups of six rhesus macaques.

One group of monkeys received remdesivir and the other animals served as an untreated comparison group. Scientists infected both groups with SARS-CoV-2.

Twelve hours later the treatment group received a dose of remdesivir intravenously, and then received a daily intravenous booster dose thereafter for the next six days.

The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.

Twelve hours after the initial treatment, the scientists examined all animals and found the six treated animals in significantly better health than the untreated group, a trend that continued during the seven-day study.

They report that one of the six treated animals showed mild breathing difficulty, whereas all six of the untreated animals showed rapid and difficult breathing.

The amount of virus found in the lungs was significantly lower in the treatment group compared to the untreated group, and SARS-CoV-2 caused less damage to the lungs in treated animals than in untreated animals.

The investigators note that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect.

The authors, from NIAID’s Rocky Mountain Laboratories in Hamilton, Montana, also note that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals. “This finding is of great significance for patient management, where a clinical improvement should not be interpreted as a lack of infectiousness,” they write. (National Institutes of Health)

YOU MAY ALSO LIKE

Diet may help preserve cognitive function

According to a recent analysis of data from two major eye disease studies, adherence to the Mediterranean diet – high in vegetables, whole grains, fish, and olive oil – correlates with higher cognitive function.

Pigs, chickens, ducks not susceptible to SARS-CoV-2

Animal disease specialists are seeking to calm fears that domestic livestock and pets can spread coronavirus, as lockdowns make protein sources scarce in some lower-income countries.

Switching on a key cancer gene could provide first curative treatment for heart disease

Researchers trying to turn off a gene that allows cancers to spread have made a surprising U-turn. By making the gene overactive and functional in the hearts of mice, they have triggered heart cell regeneration.

Large-scale analysis links glucose metabolism proteins in the brain to Alzheimer’s disease biology

A team of researchers has identified disease-specific proteins and biological processes that could be developed into both new treatment targets and fluid biomarkers.

Single mutation leads to big effects in autism-related gene

A new study in Neuron offers clues to why autism spectrum disorder (ASD) is more common in boys than in girls.

Rapid COVID-19 diagnostic test developed by Cambridge team to be deployed in hospitals

A new rapid diagnostic test for COVID-19, developed by a University of Cambridge spinout company and capable of diagnosing the infection in under 90 minutes, is being deployed at Cambridge hospitals, ahead of being launched in hospitals nationwide.